Published by Coherent Market Insights
Posted on October 7, 2021
The cardiovascular stents market is currently driven by growing demand for minimally invasive procedures across the globe. These include balloon angioplasty, percutaneous balloon catheterization, dermal endoscopic stent placement, and orthopedic laser cardiomyopathy.
There are many treatment modalities available for patients with various types of heart diseases, some of which are heart failure, myocardial infarction, congenital heart diseases, left ventricular hypertrophy (LHV), congenital cardiomyopathy, and peripheral arterial disease. Thus, high prevalence of cardiovascular diseases is expected to aid in growth of the cardiovascular stents market. According to the American Heart Association’s Heart and Stroke Statistics 2019 Update, around 48% of all adults in the U.S. suffered from some type of CVD in 2016.
Get a Sample Copy of the Report @
https://www.coherentmarketinsights.com/insight/request-sample/470
The cardiovascular stents market is also expected to witness significant growth with increasing geriatric population. According to the World Health Organization, geriatric population is expected to reach 2 billion by 2050, up from 900 million in 2015. Patients with diabetes and other long-term systemic diseases may also benefit from cardiovascular stents. according to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.
Such high prevalence of lifestyle disorders leads to approval and launch of novel stents, thereby aiding growth of the cardiovascular stents market. In January 2020, Cook Medical was awarded a new contract with the U.S. Department of Veterans Affairs, which includes products such as the Zilver PTX Drug-Eluting Peripheral Stent, Zenith aortic endografts, and associated interventional devices to treat patients with vascular disease.
Recently, in June 2021, Abbott Laboratories, another player in the cardiovascular stents market, received the U.S approval for its new addition to Xience family of drug-eluting coronary stents for one-month (as short as 28 days) dual antiplatelet therapy (DAPT) labeling for high bleeding risk (HBR) patients. In addition to the HBR indication, The company also received FDA approval and European CE mark approval for its next-generation Xience Skypoint stent. Xience Skypoint is easier to place and allows physicians to treat larger blood vessels through improved stent expansion that can open clogged vessels more effectively.
Ask for PDF sample copy of this report @
https://www.coherentmarketinsights.com/insight/request-pdf/470
The global report shows details related to the most dominant players in the global Cardiovascular Stents market, along with contact details, sales, and accurate figures of the worldwide market. Various data and detailed analyses collected from various trusted institutions of the global market are presented in the Global Research Report.
The major players covered in Cardiovascular Stents Market:
Medtronic, St. Jude Medical, Boston scientific, and Edward Lifesciences, Abbott laboratories, Johnson &Johnson, Getinge, Terumo, W. L. Gore & Associates, and Lepu Medical Technology.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Cardiovascular Stents Market 2021 Generated Opportunities, Future Scope 2028 | Medtronic, St. Jude Medical, Boston scientific, and Abbott laboratories appeared first on Gatorledger.
The cardiovascular stents market is currently driven by growing demand for minimally invasive procedures across the globe. These include balloon angioplasty, percutaneous balloon catheterization, dermal endoscopic stent placement, and orthopedic laser cardiomyopathy.
There are many treatment modalities available for patients with various types of heart diseases, some of which are heart failure, myocardial infarction, congenital heart diseases, left ventricular hypertrophy (LHV), congenital cardiomyopathy, and peripheral arterial disease. Thus, high prevalence of cardiovascular diseases is expected to aid in growth of the cardiovascular stents market. According to the American Heart Association’s Heart and Stroke Statistics 2019 Update, around 48% of all adults in the U.S. suffered from some type of CVD in 2016.
Get a Sample Copy of the Report @
https://www.coherentmarketinsights.com/insight/request-sample/470
The cardiovascular stents market is also expected to witness significant growth with increasing geriatric population. According to the World Health Organization, geriatric population is expected to reach 2 billion by 2050, up from 900 million in 2015. Patients with diabetes and other long-term systemic diseases may also benefit from cardiovascular stents. according to the study, “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition”, published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045.
Such high prevalence of lifestyle disorders leads to approval and launch of novel stents, thereby aiding growth of the cardiovascular stents market. In January 2020, Cook Medical was awarded a new contract with the U.S. Department of Veterans Affairs, which includes products such as the Zilver PTX Drug-Eluting Peripheral Stent, Zenith aortic endografts, and associated interventional devices to treat patients with vascular disease.
Recently, in June 2021, Abbott Laboratories, another player in the cardiovascular stents market, received the U.S approval for its new addition to Xience family of drug-eluting coronary stents for one-month (as short as 28 days) dual antiplatelet therapy (DAPT) labeling for high bleeding risk (HBR) patients. In addition to the HBR indication, The company also received FDA approval and European CE mark approval for its next-generation Xience Skypoint stent. Xience Skypoint is easier to place and allows physicians to treat larger blood vessels through improved stent expansion that can open clogged vessels more effectively.
Ask for PDF sample copy of this report @
https://www.coherentmarketinsights.com/insight/request-pdf/470
The global report shows details related to the most dominant players in the global Cardiovascular Stents market, along with contact details, sales, and accurate figures of the worldwide market. Various data and detailed analyses collected from various trusted institutions of the global market are presented in the Global Research Report.
The major players covered in Cardiovascular Stents Market:
Medtronic, St. Jude Medical, Boston scientific, and Edward Lifesciences, Abbott laboratories, Johnson &Johnson, Getinge, Terumo, W. L. Gore & Associates, and Lepu Medical Technology.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Cardiovascular Stents Market 2021 Generated Opportunities, Future Scope 2028 | Medtronic, St. Jude Medical, Boston scientific, and Abbott laboratories appeared first on Gatorledger.
Explore more articles in the Research Reports category
